![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
PhotoCure |
---|---|
Information provided by: | PhotoCure |
ClinicalTrials.gov Identifier: | NCT00496171 |
The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.
Condition |
---|
Healthy |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | PC CE102/07 |
Study First Received: | July 3, 2007 |
Last Updated: | January 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00496171 |
Health Authority: | Norway: Norwegian Medicines Agency; Norway: The National Committees for Research Ethics in Norway |
Signs and Symptoms Healthy |